GraceFinance · Source-backed public company research
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Nasdaq · Manufacturing · Pharmaceutical Preparations
Core research established · 4/4 core data layers currently established
What ARROWHEAD PHARMACEUTICALS, INC. does
A.Overview The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.